Holen Sie sich die Stockscreener-App
20.08
6.47%
-1.39
Handel nachbörslich:
19.62
-0.46
-2.29%
Schlusskurs vom Vortag:
$21.47
Offen:
$21.47
24-Stunden-Volumen:
68,093
Relative Volume:
0.10
Marktkapitalisierung:
$81.24M
Einnahmen:
$32.73M
Nettoeinkommen (Verlust:
$-19.52M
KGV:
-3.6327
EPS:
-5.5275
Netto-Cashflow:
$-24.61M
1W Leistung:
-1.08%
1M Leistung:
+13.48%
6M Leistung:
+6.96%
1J Leistung:
+1.20%
1-Tages-Spanne:
$19.76
$22.51
1-Wochen-Bereich:
$18.20
$22.51
52-Wochen-Spanne:
$4.971
$41.42
Cue Biopharma Inc Stock (CUE) Company Profile
Firmenname
Cue Biopharma Inc
Sektor
Branche
Telefon
617-949-2680
Adresse
40 GUEST STREET, BOSTON, MA
Compare CUE vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
20.08 | 86.86M | 32.73M | -19.52M | -24.61M | -5.5275 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-03-13 | Eingeleitet | Jefferies | Buy |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-11-21 | Eingeleitet | Piper Sandler | Overweight |
| 2022-01-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-01-03 | Eingeleitet | Craig Hallum | Buy |
| 2020-11-24 | Eingeleitet | Berenberg | Buy |
| 2020-04-09 | Eingeleitet | Stifel | Buy |
| 2020-01-28 | Eingeleitet | BTIG Research | Buy |
| 2020-01-22 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Cue Biopharma Inc Aktie (CUE) Neueste Nachrichten
CUE stock on track for best day in history — why is retail optimistic? - MSN
Cue Biopharma Analyst Ratings and Price Targets | NASDAQ:CUE - Benzinga
Cue Biopharma Inc stock (US22966J1060): capital raise, pipeline focus and conference spotlight - AD HOC NEWS
Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference - The Manila Times
Cue Biopharma CEO to present at Jefferies healthcare conference in NYC - Stock Titan
Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference | Associated Press | syndication news - Enidnews.com
Major dilution on table as Cue Biopharma (CUE) asks holders to OK warrants and 2026 plan - Stock Titan
MSN Money - MSN
Cue Biopharma Company Profile & Introduction - Moomoo
Cue Biopharma Inc stock (US22966J1060): cancer immunotherapy hopes meet volatile share price - AD HOC NEWS
Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments - The Manila Times
Cue Biopharma earnings beat by $2.22, revenue topped estimates - Investing.com Canada
Cue Biopharma receives $7.5M milestone payment from Boehringer Ingelheim - MSN
Cue Biopharma reports Q1 loss, secures $30M financing - Investing.com UK
CUE Financials: Income Statement, Balance Sheet & Cash Flow | Cue Biopharma Inc - Stock Titan
Cue Biopharma reports Q1 loss, secures $30M financing By Investing.com - Investing.com Nigeria
Cue Biopharma (CUE) boosts Q1 revenue, raises $30M and trims net loss - Stock Titan
[10-Q] Cue Biopharma, Inc. Quarterly Earnings Report - Stock Titan
Press Release: Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments - Moomoo
Cue Biopharma stock (US22966J1060): Analysts set $4 average price target - AD HOC NEWS
Cue Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Cue Biopharma, Inc. announced that it has received $29.999992 million in funding - marketscreener.com
CUE Stock Chart | CUE BIOPHARMA INC (NASDAQ:CUE) - ChartMill
Cue Biopharma (NASDAQ: CUE) asks shareholders to approve 4.64M warrant shares, 2026 equity plan - Stock Titan
TradingKey - TradingKey
Wall Street Zen Upgrades Cue Biopharma (NASDAQ:CUE) to Strong-Buy - MarketBeat
What's behind the drop in Cue Biopharma stock today? - MSN
Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Cue Biopharma Inc. R (1UC0.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cue Biopharma Grants Inducement Equity Awards to New Executive and Employees - Quiver Quantitative
New Cue Biopharma CEO gets 655,074-share option and 327,537 stock units - Stock Titan
Cue Biopharma, Inc. Common Stock (CUE) Stock Price Today & Analysis - Gotrade
Cue Biopharma (CUE) CEO Shao-Lee Lin submits initial Form 3 - Stock Titan
Cue Biopharma (CUE) CEO granted 327,537 shares and 655,074 options - Stock Titan
Number of shareholders of Cue Biopharma, Inc. – NASDAQ:CUE - TradingView
Number of shareholders of Cue Biopharma, Inc. – DUS:1UC0 - TradingView
Cue Biopharma, Inc. Dividends – DUS:1UC0 - TradingView
Cue Biopharma(CUE) Stock Options Chain | Quotes & News - Moomoo
Cue Biopharma (CUE) price target increased by 2,900.00% to 122.40 - MSN
Cue Biopharma (NASDAQ:CUE) Downgraded to Buy Rating by Wall Street Zen - MarketBeat
Why Twilio Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Sahm
Finanzdaten der Cue Biopharma Inc-Aktie (CUE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):